Documentos relacionados

1. Development and validation of HPLC method for simultaneous determination of Leflunomide and folic acid in the nanoparticulate system by reversed-phase HPLC.
2. Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs.
3. Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population.
4. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
5. [Marked improvement in rheumatoid lung nodules after treatment with tocilizumab combined with glucocorticoids and leflunomide: a case report and literature review].
6. Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.
7. Leflunomide exposure through second trimester of pregnancy: A case report.
8. Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide.
9. Rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient: A missed opportunity for pharmacist involvement.
10. Leflunomide as adjunct therapy for BK viremia management in pediatric kidney transplant recipients.